GlassScriptPhysician profile
Austin R Oblack
NPI 1790282838
$63,164.67
in general payments reported to CMS, 2019-2025
26 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $246 · 2021: $210 · 2022: $32K · 2023: $1,300 · 2024: $1,464 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $5,255 · Travel and Lodging: $3,043 · Consulting Fee: $525 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,524.99 |
| Food and Beverage | $5,255.16 |
| Travel and Lodging | $3,043.08 |
| Consulting Fee | $525.00 |
| Education | $133.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $26,240.10 | 2022-2025 | Nuplazid |
| Medtronic, INC. | $16,412.03 | 2022-2025 | Percept PC Brainsense |
| Boston Scientific Corporation | $15,402.11 | 2022-2025 | Vercise, General - Dbs |
| Amneal Pharmaceuticals LLC | $1,338.92 | 2022-2024 | Rytary |
| Abbvie INC. | $1,102.11 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $583.33 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $387.22 | 2023-2025 | |
| Mdd US Operations, LLC | $324.85 | 2024-2025 | Gocovri, Qelbree |
| Abbott Laboratories | $223.83 | 2022-2024 | Infinity, Amplatzer Talisman |
| Livanova USA, INC. | $143.23 | 2020 | |
| Biogen, INC. | $116.48 | 2019 | |
| Pfizer INC. | $116.08 | 2024-2025 | |
| Emd Serono, INC. | $113.60 | 2024 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $104.50 | 2021 | |
| Allergan, INC. | $102.36 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $82.52 | 2025 | |
| Ucb, INC. | $81.53 | 2024-2025 | Rystiggo, Zilbrysq |
| Lilly USA, LLC | $60.96 | 2024-2025 | Amyvid, Kisunla |
| Vanda Pharmaceuticals INC. | $56.96 | 2025 | Ponvory |
| Argenx US, INC. | $56.21 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $20.30 | 2025 | Vyepti |
| Genzyme Corporation | $19.57 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $19.40 | 2024 | Dysport |
| Novartis Pharmaceuticals Corporation | $19.07 | 2025 | |
| Genentech USA, INC. | $19.03 | 2024 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $18.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Oblack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.